Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ·Healthcare·Biotechnology
$10.89
+3.13%
Mkt Cap $889.16M
Analyst Ratings
No recent rating data.
Price Target (13 analysts)
$33.17
Range $27.00 – $42.00
Implied Upside
+204.7%
Consensus $33.17 vs current $10.89